Dianosic Overview
- Year Founded
-
2017
- Status
-
Private
- Employees
-
14
- Latest Deal Type
-
Debt
- (Announced)
- Investors
-
15
Dianosic General Information
Description
Developer of long-acting intranasal drug-delivery technology designed to provide targeted and sustained treatment for chronic respiratory and central nervous system diseases. The company's platform combines resorbable polymer inserts, controlled drug release, targeted nasal positioning, and Nose-to-Brain delivery capabilities, enabling pharmaceutical and healthcare partners to develop prolonged treatments for chronic respiratory and central nervous system disorders while reducing the burden of frequent medication.
Contact Information
Website
www.dianosic.comCorporate Office
- 8 Place de l'Hôpital
- Bat PH8
- 67000 Strasbourg
- France
Corporate Office
- 8 Place de l'Hôpital
- Bat PH8
- 67000 Strasbourg
- France
Dianosic Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 11. Debt - General | 02-Jan-2025 | Announced | Clinical Trials - Phase 1 | |||
| 10. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 9. Later Stage VC (Series A) | 08-Aug-2025 | Completed | Clinical Trials - Phase 1 | |||
| 8. Later Stage VC (Series A) | Cancelled | Clinical Trials - Phase 1 | ||||
| 7. Later Stage VC | 31-Oct-2022 | Completed | Clinical Trials - Phase 1 | |||
| 6. Equity Crowdfunding | 26-Nov-2021 | Completed | Clinical Trials - Phase 1 | |||
| 5. Early Stage VC | 14-Apr-2020 | Completed | Clinical Trials - Phase 1 | |||
| 4. Accelerator/Incubator | 01-Jan-2019 | Completed | Clinical Trials - Phase 1 | |||
| 3. Angel (individual) | 26-Dec-2018 | $604K | $604K | Completed | Clinical Trials - Phase 1 | |
| 2. Accelerator/Incubator | 20-Jan-2018 | Completed | Clinical Trials - Phase 1 |
Dianosic Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | ||||||||
| Ordinary | ||||||||
| Ordinary | 4,184 | $11.645104 | $147.89 | $147.89 | 1x | $147.89 | 8.23% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Dianosic Comparisons
Industry
Financing
Details
Dianosic Competitors (6)
One of Dianosic’s 6 competitors is Audion Therapeutics, a Venture Capital-Backed company based in Amsterdam, Netherlands.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Audion Therapeutics | Venture Capital-Backed | Amsterdam, Netherlands | ||||
| Biotronik | Corporate Backed or Acquired | Berlin, Germany | ||||
| Lyra Therapeutics | Formerly VC-backed | Watertown, MA | ||||
| Pfizer (Vienna) | Corporation | Vienna, Austria | ||||
| OptiNose | Private Equity-Backed | PA |
Dianosic Patents
Dianosic Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023303871-A1 | Biodegradable intranasal system for the sustained-release of an active ingredient in the intranasal cavity | Pending | 07-Jul-2022 | ||
| EP-4551201-A1 | Biodegradable intranasal system for the sustained-release of an active ingredient in the intranasal cavity | Pending | 07-Jul-2022 | ||
| US-20250387407-A1 | Biodegradable intranasal system for the sustained-release of an active ingredient in the intranasal cavity | Pending | 07-Jul-2022 | ||
| WO-2024008894-A1 | Biodegradable intranasal system for the sustained-release of an active ingredient in the intranasal cavity | Inactive | 07-Jul-2022 | ||
| FR-3137558-A1 | Implant and assembly for medical use for the introduction of such an implant into a cavity of a human or animal body | Pending | 07-Jul-2022 | A61B17/24 |
Dianosic Signals
Dianosic Investors (15)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AptarGroup | Corporation | Minority | ||
| Capital Grand Est | PE/Buyout | Minority | ||
| Finovam Gestion | Venture Capital | Minority | ||
| Noshaq | Venture Capital | Minority | ||
| Afrimobility | Venture Capital | Minority |
Dianosic FAQs
-
When was Dianosic founded?
Dianosic was founded in 2017.
-
Where is Dianosic headquartered?
Dianosic is headquartered in Strasbourg, France.
-
What is the size of Dianosic?
Dianosic has 14 total employees.
-
What industry is Dianosic in?
Dianosic’s primary industry is Drug Delivery.
-
Is Dianosic a private or public company?
Dianosic is a Private company.
-
What is Dianosic’s current revenue?
The current revenue for Dianosic is .
-
How much funding has Dianosic raised over time?
Dianosic has raised $15.2M.
-
Who are Dianosic’s investors?
AptarGroup, Capital Grand Est, Finovam Gestion, Noshaq, and Afrimobility are 5 of 15 investors who have invested in Dianosic.
-
Who are Dianosic’s competitors?
Audion Therapeutics, Biotronik, Lyra Therapeutics, Pfizer (Vienna), and OptiNose are some of the 6 competitors of Dianosic.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process